Brand Engagement Network Inc (NASDAQ: BNAI) soared during the trading session on Monday after announcing a new artificial intelligence-powered “engagement solution” deal in the pharmaceutical sector.
Shares experienced a dramatic surge, opening around US$1.78, reached a high of US$2.91 and closing at US$2.50. This represents a gain of US$1.30 or 108.75 per cent from the prior close of US$1.20 on Friday, Dec. 26. The rally was accompanied by unusually high trading volume, signalling strong interest from investors.
Brand Engagement Network (BEN) traded over 79 million shares between 9:30 am to 4 pm eastern time on the Nasdaq. Its daily average is only about a quarter million.
The catalyst for the company’s ascent on the market was described as a Vendor Services Project Agreement with a global advertising agency. This is claimed to be a subsidiary of one of the world’s top advertising holding companies. Its identity and the name of the major pharma company they are developing a “custom AI engagement communication method” for are not being disclosed for the time being.
“The identities of the pharmaceutical company and the agency remain confidential pending a formal release of the AI solution,” the company specified.
While the names of the pharma giant and ad agency remain confidential pending the solution’s formal release, BEN says the agreement is set to generate a modest US$250,000 in revenue from development services across two Statements of Work in the fourth quarter of 2025.
Moreover, monthly recurring license fees are expected to begin in the first quarter of 2026 once the AI tool is deployed.
Headquartered in Wyoming, Brand Engagement Network specializes in secure generative AI technologies such as conversational AI and human-like AI avatars. The company focuses on enhancing customer interactions for businesses while prioritizing compliance and data security, particularly in regulated industries like healthcare.
“This agreement reflects BEN’s progression in healthcare, in which our technology delivers trusted, secured, and efficient AI for pharma manufacturers, healthcare providers, and patients,” said acting chief executive, Tyler Luck, in a press release.
This agreement builds on recent momentum, including an exclusive Latin American licensing deal and the planned launch of Skye Salud — an AI healthcare platform for Mexico. Skye Salud is intended to aid with chronic disease management throughout the country.
Analysts have viewed the development as a validation of BEN’s technology, potentially opening doors to more sizeable contracts in AI-driven marketing and patient engagement. Despite a challenging year with an 87.7 per cent year-to-date decline prior to the rally, this deal has reignited optimism for the company.
The surge comes amid broader enthusiasm for AI stocks, as investors bet on technologies that promise recurring revenue and regulatory resilience. It also comes amid fears of an AI bubble and inflated valuations for companies in the space.
Going forward, BEN’s focus on secure AI positions it well in a market projected to grow exponentially. While risks like cash burn persist, this pharma deal could mark a turning point toward sustained growth and investor confidence throughout next year.
$BNAI
"Brand Engagement Network Finalizes Agreement for a Proprietary AI Engagement Solution with a LEADING GLOBAL Ad Agency"is $BNAI the next GOOGL? what if you put ALL your savings in it here at 2.8 and it goes to $100?! omg. just think of the possibilities 😍🤑
— Endless Greed (@cwa93393) December 29, 2025
Read more: Onslaught of junk AI content prompts Merriam-Webster to select ‘slop’ as its word of the year
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
